Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

The prospect of reducing the risk of some very common cancers adds the weight of evidence behind the GLP-1 agonist class, ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Here’s what to know if you’d been taking one. The FDA has banned compounded versions of GLP-1 drugs like semaglutide or tirzepatide due to safety concerns, and supplies of these copycats are ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.